相关实验视频

Updated: Jul 8, 2025

A 3D Organotypic Melanoma Spheroid Skin Model

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

与一般人群相比,被诊断患有现场黑色素瘤的患者的存活率. 一个瑞典基于人口的匹配队列研究

Ylva Naeser^1,2, Rasmus Mikiver^3,4, Christian Ingvar⁵

¹Department of Oncology, Uppsala University Hospital, Entrance 101, 751 85, Uppsala, Sweden.

EClinicalMedicine

|December 18, 2023

概括

现场黑色素瘤 (MIS) 患者的整体存活率比普通人群更好,尽管患皮肤恶性黑色素瘤 (CMM) 的风险更高. 这些发现对MIS患者来说令人放心.

科学领域:

皮肤病学皮肤病学
在瘤学瘤学.
流行病学流行病学

背景情况:

现场黑色素瘤 (MIS) 的发生率正在比皮肤恶性黑色素瘤 (CMM) 增加得更快.
与一般人群相比,MIS患者的生存结果的数据有限.

研究的目的:

研究和比较被诊断患有MIS的个体的整体存活期 (OS) 与来自一般人口的匹配对照组.
分析社会经济地位 (SES) 和并发症对生存差异的影响.

主要方法:

瑞典的一项基于人口的研究 (2001-2010) 包括7963例MIS病例和39662个匹配的对照.
排除标准包括先前的CMM诊断.
使用卡普兰-梅尔和考克斯回归分析了整体存活率,并对SES和并发症进行了调整.

主要成果:

在MIS患者中,十年生存率为77%,对照组为72%.
一般来说,MIS患者的SES和并发症率较低.
调整后的分析显示,女性患有MIS的死亡率较低 (HR 0.88),男性的死亡率也相似 (HR 0.94).
在MIS患者中,黑色素瘤特定死亡的风险是MIS患者的十倍.

结论:

被诊断为MIS的个人比普通人群具有更好的整体存活率,即使考虑到SES和并发症.
这些令人放心的发现应该传达给被诊断为MIS的患者.
尽管有更好的生存状况,但MIS患者面临着与黑色素瘤相关的死亡风险显著增加.

关键词:

伴随性疾病伴随性疾病黑色素瘤在现场发生.预后预后预测预测社会经济地位社会经济地位幸存的生存方式

更多相关视频

A Melanoma Patient-Derived Xenograft Model

A Melanoma Patient-Derived Xenograft Model

Published on: May 20, 2019

Patient Derived Cell Culture and Isolation of CD133+ Putative Cancer Stem Cells from Melanoma

Patient Derived Cell Culture and Isolation of CD133+ Putative Cancer Stem Cells from Melanoma

Published on: March 13, 2013

相关概念视频

Skin Cancer

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...